Diagnos Laboratorium Utama PT Tbk (DGNS) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Diagnos Laboratorium Utama PT Tbk IDR 36, price IDR 254, upside -85.7%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Diagnos Laboratorium Utama PT Tbk for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 129.00 IDR – 1,409 IDR · fair‑value band 35.25 IDR – 58.00 IDR · the 254.00 IDR price screens above the 36.31 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Diagnos Laboratorium Utama PT Tbk in your weekly email
Every Wednesday you see whether Diagnos Laboratorium Utama PT Tbk is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia.
Show more
PT Diagnos Laboratorium Utama Tbk provides health services using laboratories in Indonesia. The company offers laboratory tests comprising hemostasis, hepatitis, autoimmune and rheumatology, tumor markers, toxicology, lipid, allergies, TORCH, diabetes, electrolytes-blood gases, respiratory tract infection, pathology anatomy, neonatal screening, hematology, body fluids, feces, specific proteins, DNAnswer genomics, kidney function, liver function, immunology, osteoporosis, thyroid, pharmacogenomic, heart, reproduction and fertility, microbiology, drug monitoring, lungs, gastrointestinal, nutrition and heavy metals, anemia, and other bacteria; genomics; homecare services; and inspection panel tests. It also provides clinical pathology, anatomical pathology, and microbiology laboratory; and corporate health and research services. PT Diagnos Laboratorium Utama Tbk was founded in 2007 and is headquartered in Jakarta Pusat, Indonesia.
Stock analysis
Diagnos Laboratorium Utama PT Tbk (DGNS) currently trades at 254.00 IDR, while our model-based Fair Value estimate is 36.31 IDR, implying the stock looks roughly 599.3% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 99.40 IDR per share, and 0 of the 22 models we run sit above the 254.00 IDR price.
Bear case: the Growth DCF group reads lowest at 14.22 IDR, and 22 of the 22 models stay below the price. Evidence for this calculation is low.
Scenario range: 35.25 IDR (bear) to 58.00 IDR (bull), the price of 254.00 IDR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Diagnos Laboratorium Utama PT Tbk reported revenue of 167B IDR in FY2025 versus 302B IDR in FY2021, a compound −13.8%/yr. Reported net income was 2.9B IDR in FY2025, compounding −53.8%/yr from FY2021.
Key figures
Market cap 318B IDR (≈ $17.7M) · P/E ratio 4.9 · P/S ratio 0.09 · EPS (TTM) 51.84 IDR · Net margin 1.8% · Return on equity 1.7% · Return on assets (EBIT) 7.6% · Operating margin −2.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 81% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −86%, DGNS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (11.97 IDR to 148.52 IDR). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear 35.25 IDRFair Value 36.31 IDRBull 58.00 IDR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (38.06 IDR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.9%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+36.3%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in IDR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−43.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−43.9%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.37% → 3%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+51.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Indonesia: IMF forecast 2.6% a year to 2030, 2.9% from 2016 to 2025) that is about +47.2% a year for the price.
Compare Diagnos Laboratorium Utama PT Tbk with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−86% · Bottom 25%
Profitability
Return on equity (TTM)2% · Below median
Return on assets1% · Above median
Net margin (TTM)2% · Below median
Operating margin (TTM)−3% · Below median
Growth and dividend
Revenue growth12% · Above median
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)4.9× · Cheapest 25%
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)60· sector 25
PAST (return on equity)7· sector 8
HEALTH (low debt)86· sector 95
DIVIDEND (yield)0· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Diagnos Laboratorium Utama PT Tbk Fair Value". https://www.fairvalue-calculator.com/stock/DGNS
Frequently asked questions
Is Diagnos Laboratorium Utama PT Tbk (DGNS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 36.31 IDR versus a price of 254.00 IDR, about −86% upside (overvalued).
What is the fair value of DGNS?
Our model-based fair value for Diagnos Laboratorium Utama PT Tbk is 36.31 IDR (as of Sep 24, 2026), built from audited fundamentals. The current price: 254.00 IDR.
What is the quality score of DGNS?
Diagnos Laboratorium Utama PT Tbk has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Diagnos Laboratorium Utama PT Tbk (DGNS)?
Our model-based price target is the fair value of 36.31 IDR (as of Sep 24, 2026) from 22 valuation models. Cautious scenario 35.25 IDR, optimistic scenario 58.00 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Diagnos Laboratorium Utama PT Tbk stock forecast for 2026?
Our models put fair value at 36.31 IDR, about −86% upside versus a price of 254.00 IDR (overvalued). Cautious scenario 35.25 IDR, optimistic scenario 58.00 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Diagnos Laboratorium Utama PT Tbk (DGNS)?
Diagnos Laboratorium Utama PT Tbk reported trailing-twelve-month revenue of about 171B IDR (latest available figure, as of Sep 24, 2026).
What growth is priced into Diagnos Laboratorium Utama PT Tbk (DGNS)?
For today's price to be fair in a discounted-cash-flow model, Diagnos Laboratorium Utama PT Tbk would have to grow free cash flow by +51.1 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DGNS use?
Our models discount Diagnos Laboratorium Utama PT Tbk at 10.5 %: a base by market capitalisation (nano), damped by beta 0.46, country premium for Indonesia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Diagnos Laboratorium Utama PT Tbk that is +51.1 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Diagnos Laboratorium Utama PT Tbk (DGNS) delivered so far?
Over the past 5 years revenue at Diagnos Laboratorium Utama PT Tbk grew -1.9 % a year. The price currently implies +51.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Diagnos Laboratorium Utama PT Tbk (DGNS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Diagnos Laboratorium Utama PT Tbk (+51.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The free-cash-flow yield on the price is 0.81 %: that much free cash flow Diagnos Laboratorium Utama PT Tbk produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Diagnos Laboratorium Utama PT Tbk (DGNS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Diagnos Laboratorium Utama PT Tbk it is 36.31 IDR per share (as of Sep 24, 2026), against a price of 254.00 IDR. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Diagnos Laboratorium Utama PT Tbk stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DGNS trades above its calculated fair value: price 254.00 IDR, fair value 36.31 IDR, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DGNS?
No. The price is what the market pays today (254.00 IDR); the fair value is what the company's own numbers justify (36.31 IDR). For Diagnos Laboratorium Utama PT Tbk the two are 217.69 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Diagnos Laboratorium Utama PT Tbk worth?
The market values Diagnos Laboratorium Utama PT Tbk at about 318B IDR (market capitalisation, as of Sep 24, 2026). Per share that is 254.00 IDR; our models calculate a fair value of 36.31 IDR per share.
What do the bullish and bearish scenarios say about DGNS?
Our models span a range for Diagnos Laboratorium Utama PT Tbk: cautious scenario 35.25 IDR, base 36.31 IDR, optimistic 58.00 IDR per share (as of Sep 24, 2026, price 254.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DGNS?
Diagnos Laboratorium Utama PT Tbk trades at a price-to-earnings ratio of 4.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 36.31 IDR is built from several models across several years.
How solid is the balance sheet of Diagnos Laboratorium Utama PT Tbk (DGNS)?
Balance-sheet figures for Diagnos Laboratorium Utama PT Tbk (as of Sep 24, 2026): return on equity 1.7%, debt of 0.29 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is DGNS from its 52-week high?
Diagnos Laboratorium Utama PT Tbk trades at 254.00 IDR, about 23% below its 52-week high of 328.00 IDR and 81% above the low of 140.00 IDR (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 36.31 IDR is for.
Which stocks are comparable to Diagnos Laboratorium Utama PT Tbk?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Diagnos Laboratorium Utama PT Tbk stock attractive at the current price?
The data as of Sep 24, 2026: price 254.00 IDR, calculated fair value 36.31 IDR (−86%), Quality Score 53/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DGNS calculated?
We run Diagnos Laboratorium Utama PT Tbk through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 36.31 IDR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Diagnos Laboratorium Utama PT Tbk itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The closing price on Sep 24, 2026 was 254.00 IDR. Our model-based fair value is 36.31 IDR, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Diagnos Laboratorium Utama PT Tbk right now?
The price sits above even our optimistic bull case (58.00 IDR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Diagnos Laboratorium Utama PT Tbk
How large is the market capitalisation of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The market capitalisation of Diagnos Laboratorium Utama PT Tbk is 318B IDR (≈ $17.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The price-to-sales ratio of Diagnos Laboratorium Utama PT Tbk is 0.09 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Diagnos Laboratorium Utama PT Tbk (DGNS)?
Earnings per share at Diagnos Laboratorium Utama PT Tbk are 51.84 IDR (price ÷ EPS = P/E 4.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The net margin of Diagnos Laboratorium Utama PT Tbk is 1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The return on equity (ROE) of Diagnos Laboratorium Utama PT Tbk is 1.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Diagnos Laboratorium Utama PT Tbk (DGNS)?
On an EBIT basis the return on assets of Diagnos Laboratorium Utama PT Tbk is 7.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Diagnos Laboratorium Utama PT Tbk (DGNS)?
The operating margin of Diagnos Laboratorium Utama PT Tbk is −2.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Diagnos Laboratorium Utama PT Tbk (DGNS)?
Revenue at Diagnos Laboratorium Utama PT Tbk is growing +11.9% versus a year earlier (3y avg −4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Diagnos Laboratorium Utama PT Tbk (DGNS)?
Earnings per share at Diagnos Laboratorium Utama PT Tbk are growing +19.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Diagnos Laboratorium Utama PT Tbk (DGNS) carry?
The net debt of Diagnos Laboratorium Utama PT Tbk is 70.8B IDR (fiscal year 2025, ≈ 27.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Diagnos Laboratorium Utama PT Tbk in the live analysis
One click puts Diagnos Laboratorium Utama PT Tbk on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
